**Charité/BIH – Pilot Program Call for Proposals**

The *Israel Innovation Authority* (IIA) and the *Charité - Universitätsmedizin Berlin* (Charité) invite interested Israeli companies to submit applications to pilot healthcare-related technology solutions with Charité.

Charité and the IIA are seeking to advance healthcare by helping Israeli companies get the evidence and assistance they need to fine-tune their development and to enter and be successful in the European healthcare market.

Charité would serve as a real-world living laboratory for the Israeli companies to test and improve an existing process, service, or product; or to apply a new process to health care for the first time.

The goal of this collaboration is to accelerate the availability of medical innovations to the public, introduce Israeli healthcare technology to Europe, and advance the development and deployment of discoveries for the benefit of patients everywhere**.**

The **IIA** provides resources to aid technology advancement for Israeli companies.

Together with the **Berlin Institute of Health (BIH)**, **Charité** provides expertise and excellence in clinical care, clinical studies, and R&D activities. Charité is one of the largest university hospitals in Europe. All of our clinical care, research, and teaching are delivered by physicians and researchers of the highest international standard. Charité proudly lays claim to more than half of all German Nobel Prize winners in Physiology or Medicine, including Emil von Behring, Robert Koch, and Paul Ehrlich. Charité is internationally renowned for its excellence in teaching and training. Charité – Universitätsmedizin Berlin represents a single medical faculty, which serves both Humboldt Universtität zu Berlin and Freie Universität Berlin. Charité extends over four campuses and has close to 100 different Departments and Institutes, which make up a total of 17 different Charité Centers. Having marked its 300th anniversary in 2010, Charité is now one of the largest employers in Berlin, employing 14,576 staff (18,010 including its subsidiaries), and with a total annual turnover of €1.8 billion.

**The health themes of interest to Charite and BIH include** digital or mobile healthcare technology solutions and applications and innovative medical devices (wearables) for diagnostic and/or therapeutic purpose, especially in the following areas:

* Patient and public involvement and engagement – publicly guided medical research or solutions
* Mobile health applications
* Combining MedTech with biological and biotech solutions
* Medical wearable devices – innovative medical technology, designed to solve unmet needs in clinical care

**Deadline for Expression of Interest (EOI) form submissions: 02/07/2020**

**Supported activities** may include: piloting, testing (of different kinds; including in real-world conditions), validation, trials, performance verification, device iteration, product and interface customization, pre-pilot activities, R&D activities needed for the pilot, optimizing the clinical use of a given technology/product, identifying the parameters of the product/technology and potential use cases, optimizing user interfaces, etc.

**What support do the IIA and Charité offer?**

Successful Israeli applicant companies will receive funding from the IIA and in-kind services from HHC.

The IIA can support R&D performing companies, registered and operating in Israel, with a grant of up to 50% of the approved Pilot Expenses Budget, according to its regulations and procedures.

When a project eventually results in sales of a product, service, or process, the financial support must be repaid in royalties to the *Israel Innovation Authority* according to its regulations. In general, royalties are paid at rates beginning at 3% of sales, depending on various criteria. Royalties are payable until 100% of the amount of the grant has been repaid with interest as provided in the applicable regulations. If the project does not result in sales, no repayment is required.

Charite will provide in-kind services, expertise, and/or use of facilities. Examples for such in-kind support can include:

* Usage of unique facilities for beta-sites operations;
* Access to real-field-conditions for the tested innovation;
* Usage of internal services, expertise, knowledge, or equipment;
* Access to unique data, data-sets, engines, devices, skills;
* Possibility to recruit patients, experimenters, tools, etc.;
* Experts' and consultants' time to guide, co-develop and, identify the parameters of the product/technology for testing or potential use cases;
* Regulatory and legal guidance to ensure full compliance;
* Assistance in co-commercializing the product; for example, through joint work with relevant local business partners (companies, investors, distributors, etc.) that are part of the Charité network.

Charite would fund its in-kind assistance for the project and make it accessible through an applicable agreement with the selected Israeli companies. If according to the arrangement the Israeli company needs to pay Charite, this cost could not be funded by the IIA.

An appropriate agreement between successful applicant companies and Charite will need to be signed before project initiation.

**Process and Timeline**

|  |  |
| --- | --- |
| Program launch | 10/05/2020 |
| Applicants submit Expression of Interest (EOI) form | 09/07/2020 |
| IIA and Charité invite shortlisted applicants to submit a full application | 23/08/2020 |
| Shortlisted applicants submit a full online application to the IIA and program outline and budget in English to  Charité | 13/09/2020 |
| IIA and Charité notify selected applicants of approval | ~ December 2020 |
| Agreement signing and submission to the IIA | ~ January 2020 |
| Project launching | ~ February 2020 |

**Contacts**

|  |  |
| --- | --- |
| **Charite**  Maria Ronnefarth Berlin Institute of Health (BIH) Deputy Head, Clinical Research Unit (CRU) Research Associate, Physician Charité Campus Mitte, Charitéplatz 1 10117 Berlin Tel: +49 30 450 643635 Fax: +49 450 754 3911 Email: [maria.roennefarth@charite.de](mailto:maria.roennefarth@charite.de)  [www.bihealth.org](http://www.bihealth.org/) | [www.charite.de](http://www.charite.de/) | **Israel**  Ms. Ruth Friedel Director of Planning Unit International Collaboration Division Israel Innovation Authority  [PLU@innovationisrael.org.il](mailto:PLU@innovationisrael.org.il)  Tel: +972-3-5118190 |

Attached: Expression of Interest (EOI) form